Biora Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.45) Estimate, Sales $542.000K
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics (NASDAQ:BIOR) reported a Q1 2024 GAAP EPS of $(0.14), significantly beating the analyst estimate of $(0.45). This represents a 77.78% improvement over the same period last year. The company also reported $542,000 in sales for the quarter.
May 15, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics reported a Q1 2024 GAAP EPS of $(0.14), beating the analyst estimate of $(0.45) by 68.89%. This is a significant improvement from the $(0.63) per share loss in the same period last year. The company also reported $542,000 in sales.
The significant beat on EPS estimates and the substantial year-over-year improvement in losses are likely to positively impact BIOR's stock price in the short term. The reported sales figure, while modest, also contributes to a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100